[Show abstract][Hide abstract] ABSTRACT: ObjectiveTo evaluate the clinical effects and adverse reactions of Docetaxel and Thalidomide in treating advanced androgen independent
prostate cancer (AIPC).
Methods12 cases of advanced AIPC were given a combined treatment of Docetaxel and Thalidomide, with Docetaxel 75 mg/m2 on day 1 and Thalidomide 100 mg per day as initial dose and 300 mg as terminal dose by an increase of 50 mg every week.
ResultsThe post-treatment values of prostate specific antigen (PSA) were normal (< 4 ng/L) in 10 patients, less than 50% of pretreatment
value in one patient, and no significant change in one patient. The median survival time was 14 months and period of the median
symptoms reduction was 16.3 months. Common adverse reactions were tolerable, including nausea, vomiting, leukopenia, anemia
ConclusionThe regimen of Docetaxel combined with Thalidomide was effective and tolerable in the treatment of advanced AIPC.
No preview · Article · May 2009 · The Chinese-German Journal of Clinical Oncology